{"hands_on_practices": [{"introduction": "Before incorporating any new diagnostic tool into clinical practice, we must first quantify its fundamental performance. This exercise provides a foundational hands-on experience in evaluating a diagnostic test's intrinsic accuracy from raw experimental data. By calculating sensitivity and specificity from a contingency table, you will learn to measure a test's ability to correctly identify those with and without a disease, a critical first step in evidence-based medicine [@problem_id:4952579].", "problem": "A new bedside screening assay for Disease $X$ is evaluated in an urgent care setting by comparing it to a reference standard that classifies disease presence or absence with near-perfect accuracy. The evaluation yields a $2 \\times 2$ contingency summary as follows: among individuals confirmed to have Disease $X$ by the reference standard, the assay produced $288$ true positives and $32$ false negatives; among individuals confirmed not to have Disease $X$, the assay produced $102$ false positives and $578$ true negatives. Using only core definitions of diagnostic test properties, first compute the sensitivity and specificity of the assay from these counts. Then, explain in words what each metric quantifies and what the computed values imply for using this assay to help rule in or rule out Disease $X$ during differential diagnosis in this clinical context. Finally, report a single summary performance number by computing the Youden index $J$ from your computed sensitivity and specificity. Express the final reported value of $J$ as a decimal rounded to four significant figures. Do not include any units with your final number.", "solution": "The problem statement is subjected to validation.\n\n**Step 1: Extract Givens**\n- A new bedside screening assay for Disease $X$ is evaluated against a reference standard.\n- The evaluation data is presented as a $2 \\times 2$ contingency summary.\n- For individuals with Disease $X$ (condition positive):\n    - True Positives (TP): $288$\n    - False Negatives (FN): $32$\n- For individuals without Disease $X$ (condition negative):\n    - False Positives (FP): $102$\n    - True Negatives (TN): $578$\n- The task is to:\n    1. Compute the sensitivity and specificity of the assay.\n    2. Explain the meaning of these metrics and their clinical implications for ruling in or ruling out Disease $X$.\n    3. Compute the Youden index, $J$, from the sensitivity and specificity.\n    4. Report $J$ as a decimal rounded to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding:** The problem is based on fundamental principles of biostatistics and epidemiology used for evaluating diagnostic tests. The concepts of sensitivity, specificity, true/false positives/negatives, and the Youden index are standard, well-defined metrics in clinical medicine. The problem is scientifically sound.\n- **Well-Posed:** All necessary data (TP, FN, FP, TN) are explicitly provided to calculate the requested metrics. The instructions are clear and lead to a unique, stable, and meaningful solution.\n- **Objective:** The problem is stated using objective, quantitative language, free of subjective claims or bias.\n\n**Step 3: Verdict and Action**\nThe problem is valid as it is scientifically grounded, well-posed, and objective. A complete solution will be provided.\n\n**Solution Derivation**\n\nThe analysis begins with the definitions of sensitivity and specificity, which are core measures of a diagnostic test's performance.\n\nLet $D^+$ be the event that an individual has Disease $X$, and $D^-$ be the event that an individual does not have Disease $X$.\nLet $T^+$ be the event that the assay yields a positive result, and $T^-$ be the event that the assay yields a negative result.\n\nThe provided data can be summarized as follows:\n- Number of True Positives (TP): Number of individuals with the disease who test positive, $N(T^+ \\cap D^+) = 288$.\n- Number of False Negatives (FN): Number of individuals with the disease who test negative, $N(T^- \\cap D^+) = 32$.\n- Number of False Positives (FP): Number of individuals without the disease who test positive, $N(T^+ \\cap D^-) = 102$.\n- Number of True Negatives (TN): Number of individuals without the disease who test negative, $N(T^- \\cap D^-) = 578$.\n\nThe total number of individuals with the disease is the sum of true positives and false negatives:\n$$N(D^+) = \\text{TP} + \\text{FN} = 288 + 32 = 320$$\n\nThe total number of individuals without the disease is the sum of true negatives and false positives:\n$$N(D^-) = \\text{TN} + \\text{FP} = 578 + 102 = 680$$\n\n**1. Computation of Sensitivity and Specificity**\n\nSensitivity (also known as the true positive rate) is the probability that the test is positive, given that the individual has the disease. It is calculated as:\n$$ \\text{Sensitivity} = P(T^+ | D^+) = \\frac{\\text{TP}}{\\text{TP} + \\text{FN}} $$\nSubstituting the given values:\n$$ \\text{Sensitivity} = \\frac{288}{288 + 32} = \\frac{288}{320} = \\frac{9}{10} = 0.9 $$\n\nSpecificity (also known as the true negative rate) is the probability that the test is negative, given that the individual does not have the disease. It is calculated as:\n$$ \\text{Specificity} = P(T^- | D^-) = \\frac{\\text{TN}}{\\text{TN} + \\text{FP}} $$\nSubstituting the given values:\n$$ \\text{Specificity} = \\frac{578}{578 + 102} = \\frac{578}{680} = \\frac{17}{20} = 0.85 $$\n\n**2. Explanation of Metrics and Clinical Implications**\n\n**Sensitivity:** The computed sensitivity of the assay is $0.9$, or $90\\%$. This value quantifies the test's ability to correctly identify individuals who have Disease $X$. Specifically, it means that if $100$ individuals with Disease $X$ were tested, the assay would correctly identify approximately $90$ of them as positive, while $10$ would be missed (false negatives). A high sensitivity is critical when the consequences of missing a diagnosis (a false negative) are severe. In the context of differential diagnosis, a test with high sensitivity is particularly useful for \"ruling out\" a disease. If such a test returns a negative result, it provides strong evidence that the patient does not have the disease, because the test rarely misses the disease when it is present. The high sensitivity of $0.9$ suggests this assay is effective for this purpose.\n\n**Specificity:** The computed specificity of the assay is $0.85$, or $85\\%$. This value quantifies the test's ability to correctly identify individuals who do not have Disease $X$. It means that if $100$ individuals without Disease $X$ were tested, the assay would correctly identify approximately $85$ of them as negative, while $15$ would receive an incorrect positive result (false positives). A high specificity is important to avoid unnecessary follow-up procedures, costs, and patient anxiety associated with a false positive diagnosis. In differential diagnosis, a test with high specificity is useful for \"ruling in\" a disease. If such a test returns a positive result, it provides strong evidence that the patient does indeed have the disease, because the test rarely gives a positive result for healthy individuals. The specificity of $0.85$ is reasonably good, but indicates a non-trivial false positive rate ($15\\%$). Thus, a positive result from this assay strengthens the suspicion of Disease $X$, but may warrant confirmation with a more definitive test before initiating treatment, depending on the clinical context.\n\n**3. Computation of the Youden Index**\n\nThe Youden index, $J$, is a single statistic that summarizes the performance of a diagnostic test. It measures the test's ability to discriminate between those with and without the disease. It is defined as:\n$$ J = \\text{Sensitivity} + \\text{Specificity} - 1 $$\nThe value of $J$ ranges from $0$ to $1$, where $1$ represents a perfect test and $0$ represents a test with no discriminative ability (equivalent to chance).\n\nUsing the computed values for sensitivity and specificity:\n$$ J = 0.9 + 0.85 - 1 $$\n$$ J = 1.75 - 1 = 0.75 $$\n\nThe problem requires the final value to be expressed as a decimal rounded to four significant figures. The value $0.75$ has two significant figures. To express it with four, we append trailing zeros.\n$$ J = 0.7500 $$\nThis value indicates a good, but not perfect, level of diagnostic performance.", "answer": "$$\\boxed{0.7500}$$", "id": "4952579"}, {"introduction": "While sensitivity and specificity are crucial measures of a test's accuracy, they don't directly answer the clinician's most pressing question: \"Given this test result, what is the probability my patient has the disease?\" This practice bridges that gap by introducing Positive and Negative Predictive Values ($PPV$ and $NPV$). You will see firsthand how the prevalence of a disease in a population profoundly impacts the meaning of a positive or negative result, highlighting why context is everything in diagnostic reasoning [@problem_id:4952592].", "problem": "A primary care clinic is evaluating a new point-of-care polymerase chain reaction (PCR) test for influenza in adults presenting with acute respiratory symptoms during peak season. In this clinic population, the estimated disease prevalence is $0.12$. The test’s sensitivity is $0.92$ and its specificity is $0.88$. Using only the fundamental definitions of sensitivity, specificity, and disease prevalence, together with the rules of conditional probability, derive expressions for the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of the test in terms of sensitivity, specificity, and prevalence. Then compute the PPV and NPV at the given prevalence. Finally, interpret what the computed PPV and NPV mean for clinical decision-making in this setting. Express both PPV and NPV as decimal fractions and round your answers to four significant figures.", "solution": "The problem is to derive and compute the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) for a new influenza test, given its sensitivity, specificity, and the disease prevalence in a specific population. The problem is valid as it is scientifically grounded in probability theory and epidemiology, well-posed with all necessary data provided, and objective in its formulation.\n\nLet $D$ be the event that a patient has influenza, and $D^c$ be the event that the patient does not have influenza.\nLet $T^+$ be the event of a positive test result, and $T^-$ be the event of a negative test result.\n\nThe givens from the problem statement are:\n-   Prevalence of influenza, $P(D) = P = 0.12$.\n-   Sensitivity of the test, $Se = P(T^+ | D) = 0.92$.\n-   Specificity of the test, $Sp = P(T^- | D^c) = 0.88$.\n\nFrom these, we can deduce a few other probabilities:\n-   The probability of not having the disease is $P(D^c) = 1 - P(D) = 1 - P = 1 - 0.12 = 0.88$.\n-   The probability of a negative test given the patient has the disease (False Negative Rate) is $P(T^- | D) = 1 - Se = 1 - 0.92 = 0.08$.\n-   The probability of a positive test given the patient does not have the disease (False Positive Rate) is $P(T^+ | D^c) = 1 - Sp = 1 - 0.88 = 0.12$.\n\n**Derivation of PPV and NPV**\n\nThe Positive Predictive Value (PPV) is the probability that a patient has the disease given a positive test result, i.e., $P(D | T^+)$.\nThe Negative Predictive Value (NPV) is the probability that a patient does not have the disease given a negative test result, i.e., $P(D^c | T^-)$.\n\nWe will use the definition of conditional probability, $P(A|B) = \\frac{P(A \\cap B)}{P(B)}$, and the law of total probability. These principles combined form Bayes' theorem, which is the foundation for these derivations.\n\n**Derivation of PPV:**\nBy definition, $PPV = P(D | T^+) = \\frac{P(D \\cap T^+)}{P(T^+)}$.\nThe numerator, the joint probability of having the disease and testing positive, can be expressed as $P(D \\cap T^+) = P(T^+ | D) P(D) = Se \\cdot P$.\nThe denominator, the total probability of a positive test, is found using the law of total probability by conditioning on the disease status:\n$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$\n$P(T^+) = (Se \\cdot P) + ((1 - Sp) \\cdot (1 - P))$\nSubstituting the expressions for the numerator and denominator, we get the general formula for PPV:\n$$PPV = \\frac{Se \\cdot P}{Se \\cdot P + (1 - Sp) \\cdot (1 - P)}$$\n\n**Derivation of NPV:**\nBy definition, $NPV = P(D^c | T^-) = \\frac{P(D^c \\cap T^-)}{P(T^-)}$.\nThe numerator, the joint probability of not having the disease and testing negative, can be expressed as $P(D^c \\cap T^-) = P(T^- | D^c) P(D^c) = Sp \\cdot (1 - P)$.\nThe denominator, the total probability of a negative test, is found using the law of total probability:\n$P(T^-) = P(T^- | D^c) P(D^c) + P(T^- | D) P(D)$\n$P(T^-) = (Sp \\cdot (1 - P)) + ((1 - Se) \\cdot P)$\nSubstituting the expressions for the numerator and denominator, we get the general formula for NPV:\n$$NPV = \\frac{Sp \\cdot (1 - P)}{Sp \\cdot (1 - P) + (1 - Se) \\cdot P}$$\n\n**Computation of PPV and NPV**\n\nUsing the given values: $P = 0.12$, $Se = 0.92$, and $Sp = 0.88$.\n\n**PPV Calculation:**\n$$PPV = \\frac{0.92 \\cdot 0.12}{0.92 \\cdot 0.12 + (1 - 0.88) \\cdot (1 - 0.12)}$$\n$$PPV = \\frac{0.1104}{0.1104 + (0.12) \\cdot (0.88)}$$\n$$PPV = \\frac{0.1104}{0.1104 + 0.1056}$$\n$$PPV = \\frac{0.1104}{0.216}$$\n$$PPV = 0.511111...$$\nRounding to four significant figures, $PPV \\approx 0.5111$.\n\n**NPV Calculation:**\n$$NPV = \\frac{0.88 \\cdot (1 - 0.12)}{0.88 \\cdot (1 - 0.12) + (1 - 0.92) \\cdot 0.12}$$\n$$NPV = \\frac{0.88 \\cdot 0.88}{0.88 \\cdot 0.88 + (0.08) \\cdot (0.12)}$$\n$$NPV = \\frac{0.7744}{0.7744 + 0.0096}$$\n$$NPV = \\frac{0.7744}{0.784}$$\n$$NPV = 0.987755...$$\nRounding to four significant figures, $NPV \\approx 0.9878$.\n\n**Interpretation for Clinical Decision-Making**\n\nThe computed Positive Predictive Value is $PPV \\approx 0.5111$, or $51.11\\%$. This signifies that for an adult patient with acute respiratory symptoms in this clinic during peak season, a positive test result confers a $51.11\\%$ probability of actually having influenza. While this increases the post-test probability from the pre-test probability (prevalence) of $12\\%$, it is not high enough to be diagnostically conclusive. Nearly half ($48.89\\%$) of the positive results are false positives. Therefore, a clinician should not rely solely on a positive result to initiate treatment (e.g., antiviral medication) without considering other clinical findings or, if necessary, a more accurate confirmatory test.\n\nThe computed Negative Predictive Value is $NPV \\approx 0.9878$, or $98.78\\%$. This indicates that if a patient tests negative, there is a $98.78\\%$ probability that they do not have influenza. This is a very high degree of certainty. A negative result is extremely reliable for ruling out influenza. In a clinical context, this high NPV allows the clinician to confidently exclude influenza from the differential diagnosis and investigate other causes for the patient's symptoms, thus avoiding unnecessary antiviral therapy.\n\nIn summary, for this particular test in this population, it is much more powerful as a tool to rule out influenza (high NPV) than to rule it in (modest PPV).", "answer": "$$\\boxed{\\begin{pmatrix} 0.5111  0.9878 \\end{pmatrix}}$$", "id": "4952592"}, {"introduction": "The ultimate goal of clinical reasoning is to make the best possible decision for a patient. This advanced practice moves beyond interpreting tests to actively deciding a course of action. By integrating pre-test probability, test characteristics, and patient-centered values (utilities), you will learn to formally calculate decision thresholds—the precise probabilities at which the optimal strategy shifts from observing, to testing, or to treating empirically. This exercise formalizes the complex trade-offs clinicians navigate daily, turning intuitive judgment into a structured, evidence-based choice [@problem_id:4952591].", "problem": "A primary care clinician is evaluating a $22$-year-old with sore throat and fever. The clinician considers the working diagnosis to be Group A streptococcal pharyngitis. Let $p$ denote the pre-test probability of disease. The clinician can either observe without testing, test and then act on the result (treat if the test is positive, do not treat if the test is negative), or treat without testing. Assume all decisions are made to maximize expected utility, where utilities are on a normalized $[0,1]$ scale representing patient-centered preferences.\n\nYou are given the following utilities for the four end states:\n- Treat with disease present: $U_{\\mathrm{T|D}} = 0.68$.\n- Do not treat with disease present: $U_{\\mathrm{NT|D}} = 0.50$.\n- Treat with no disease: $U_{\\mathrm{T|\\neg D}} = 0.98$.\n- Do not treat with no disease: $U_{\\mathrm{NT|\\neg D}} = 1.00$.\n\nThe rapid antigen detection test has sensitivity $s = 0.85$ and specificity $c = 0.95$. Undergoing the test carries a small disutility $K = 0.003$ that applies regardless of the result.\n\nStarting only from the fundamental definitions of expected utility and basic probability, and assuming the post-test policy “treat if positive, do not treat if negative,” derive the pre-test probability threshold below which it is better to observe than to test (the testing threshold), and the pre-test probability threshold above which it is better to treat without testing than to observe (the treatment threshold). Then, for a pre-test probability $p_0 = 0.06$, decide the optimal action among observe, test (with result-contingent action as specified), or treat.\n\nAnswer specification:\n- Report the testing threshold and the treatment threshold as decimals in the interval $[0,1]$, each rounded to four significant figures.\n- Express all probabilities as decimals (not percentages).\n- Encode the decision as $0$ for observe, $1$ for test, and $2$ for treat.\n- Present your final answer as a single row matrix $\\begin{pmatrix}\\text{testing threshold}  \\text{treatment threshold}  \\text{decision code}\\end{pmatrix}$.", "solution": "The problem requires a decision analysis to determine the optimal strategy among three choices: observing, testing, or treating a patient with a pre-test probability $p$ of having Group A streptococcal pharyngitis. The decision is based on maximizing the expected utility.\n\nFirst, we establish the fundamental definitions and given values.\nLet $D$ be the event that the patient has the disease, and $\\neg D$ be the event that the patient does not have the disease. The pre-test probability of disease is $P(D) = p$, and the probability of no disease is $P(\\neg D) = 1-p$.\n\nThe utilities for the four possible outcomes are given:\n- Utility of treating a patient with the disease: $U_{\\mathrm{T|D}} = 0.68$.\n- Utility of not treating a patient with the disease: $U_{\\mathrm{NT|D}} = 0.50$.\n- Utility of treating a patient without the disease: $U_{\\mathrm{T|\\neg D}} = 0.98$.\n- Utility of not treating a patient without the disease: $U_{\\mathrm{NT|\\neg D}} = 1.00$.\n\nThe rapid antigen detection test has the following characteristics:\n- Sensitivity: $s = P(\\text{Test}+ | D) = 0.85$.\n- Specificity: $c = P(\\text{Test}- | \\neg D) = 0.95$.\nFrom these, we can deduce:\n- False negative rate: $P(\\text{Test}- | D) = 1-s = 1 - 0.85 = 0.15$.\n- False positive rate: $P(\\text{Test}+ | \\neg D) = 1-c = 1 - 0.95 = 0.05$.\n\nThe disutility associated with undergoing the test is $K = 0.003$.\n\nWe will now derive the expected utility (EU) for each of the three strategies as a function of the pre-test probability $p$.\n\n1.  **Expected Utility of Observing (No Treatment, No Test)**\nThe patient is not treated, regardless of their disease state. The expected utility, $EU_{\\text{observe}}$, is the weighted average of the utilities of the two possible outcomes (disease present, disease absent).\n$$EU_{\\text{observe}}(p) = P(D) \\cdot U_{\\mathrm{NT|D}} + P(\\neg D) \\cdot U_{\\mathrm{NT|\\neg D}}$$\n$$EU_{\\text{observe}}(p) = p \\cdot U_{\\mathrm{NT|D}} + (1-p) \\cdot U_{\\mathrm{NT|\\neg D}}$$\nSubstituting the given values:\n$$EU_{\\text{observe}}(p) = p(0.50) + (1-p)(1.00) = 0.50p + 1.00 - 1.00p = 1.00 - 0.50p$$\n\n2.  **Expected Utility of Treating (Empiric Treatment, No Test)**\nThe patient is treated, regardless of their disease state. The expected utility, $EU_{\\text{treat}}$, is the weighted average of the utilities of the two possible outcomes.\n$$EU_{\\text{treat}}(p) = P(D) \\cdot U_{\\mathrm{T|D}} + P(\\neg D) \\cdot U_{\\mathrm{T|\\neg D}}$$\n$$EU_{\\text{treat}}(p) = p \\cdot U_{\\mathrm{T|D}} + (1-p) \\cdot U_{\\mathrm{T|\\neg D}}$$\nSubstituting the given values:\n$$EU_{\\text{treat}}(p) = p(0.68) + (1-p)(0.98) = 0.68p + 0.98 - 0.98p = 0.98 - 0.30p$$\n\n3.  **Expected Utility of Testing**\nThe strategy is to test, then treat if the result is positive and not treat if the result is negative. The overall expected utility, $EU_{\\text{test}}$, must account for the outcomes contingent on the test result, as well as the disutility of the test itself.\n\nLet's calculate the expected utility of the post-test actions. A patient with the disease (probability $p$) will test positive with probability $s$ and be treated (utility $U_{\\mathrm{T|D}}$), or test negative with probability $1-s$ and not be treated (utility $U_{\\mathrm{NT|D}}$). A patient without the disease (probability $1-p$) will test positive with probability $1-c$ and be treated (utility $U_{\\mathrm{T|\\neg D}}$), or test negative with probability $c$ and not be treated (utility $U_{\\mathrm{NT|\\neg D}}$).\n\nSumming the utilities of these four mutually exclusive events, weighted by their probabilities:\nThe probability of $D$ and Test+ is $P(D)P(\\text{Test+}|D) = ps$.\nThe probability of $D$ and Test- is $P(D)P(\\text{Test-}|D) = p(1-s)$.\nThe probability of $\\neg D$ and Test+ is $P(\\neg D)P(\\text{Test+}|\\neg D) = (1-p)(1-c)$.\nThe probability of $\\neg D$ and Test- is $P(\\neg D)P(\\text{Test-}|\\neg D) = (1-p)c$.\n\nThe expected utility before considering the test disutility is:\n$$EU_{\\text{test}}^*(p) = ps \\cdot U_{\\mathrm{T|D}} + p(1-s) \\cdot U_{\\mathrm{NT|D}} + (1-p)(1-c) \\cdot U_{\\mathrm{T|\\neg D}} + (1-p)c \\cdot U_{\\mathrm{NT|\\neg D}}$$\nThis can be regrouped as:\n$$EU_{\\text{test}}^*(p) = p[s \\cdot U_{\\mathrm{T|D}} + (1-s) \\cdot U_{\\mathrm{NT|D}}] + (1-p)[(1-c) \\cdot U_{\\mathrm{T|\\neg D}} + c \\cdot U_{\\mathrm{NT|\\neg D}}]$$\nThe total expected utility for testing is $EU_{\\text{test}}(p) = EU_{\\text{test}}^*(p) - K$.\nSubstituting the values:\n$$EU_{\\text{test}}(p) = p[0.85(0.68) + 0.15(0.50)] + (1-p)[0.05(0.98) + 0.95(1.00)] - 0.003$$\n$$EU_{\\text{test}}(p) = p[0.578 + 0.075] + (1-p)[0.049 + 0.95] - 0.003$$\n$$EU_{\\text{test}}(p) = p(0.653) + (1-p)(0.999) - 0.003$$\n$$EU_{\\text{test}}(p) = 0.653p + 0.999 - 0.999p - 0.003 = 0.996 - 0.346p$$\n\nNow we derive the thresholds as defined in the problem.\n\n**Testing Threshold**\nThis is the pre-test probability, let's call it $p_{\\text{test}}$, at which the expected utility of observing is equal to the expected utility of testing. Below this threshold, observing is preferred.\n$$EU_{\\text{observe}}(p_{\\text{test}}) = EU_{\\text{test}}(p_{\\text{test}})$$\n$$1.00 - 0.50p_{\\text{test}} = 0.996 - 0.346p_{\\text{test}}$$\n$$1.00 - 0.996 = (0.50 - 0.346)p_{\\text{test}}$$\n$$0.004 = 0.154p_{\\text{test}}$$\n$$p_{\\text{test}} = \\frac{0.004}{0.154} = \\frac{4}{154} = \\frac{2}{77} \\approx 0.02597402...$$\nRounded to four significant figures, the testing threshold is $0.02597$.\n\n**Treatment Threshold**\nThis is the pre-test probability, let's call it $p_{\\text{treat}}$, at which the expected utility of observing is equal to the expected utility of treating. The problem states that above this threshold, it is better to treat than to observe.\n$$EU_{\\text{observe}}(p_{\\text{treat}}) = EU_{\\text{treat}}(p_{\\text{treat}})$$\n$$1.00 - 0.50p_{\\text{treat}} = 0.98 - 0.30p_{\\text{treat}}$$\n$$1.00 - 0.98 = (0.50 - 0.30)p_{\\text{treat}}$$\n$$0.02 = 0.20p_{\\text{treat}}$$\n$$p_{\\text{treat}} = \\frac{0.02}{0.20} = 0.1$$\nRounded to four significant figures, the treatment threshold is $0.1000$.\n\n**Optimal Action for $p_0 = 0.06$**\nTo find the optimal action for a pre-test probability $p_0 = 0.06$, we must compare the expected utilities of the three strategies at this probability.\n$$EU_{\\text{observe}}(0.06) = 1.00 - 0.50(0.06) = 1.00 - 0.03 = 0.97$$\n$$EU_{\\text{treat}}(0.06) = 0.98 - 0.30(0.06) = 0.98 - 0.018 = 0.962$$\n$$EU_{\\text{test}}(0.06) = 0.996 - 0.346(0.06) = 0.996 - 0.02076 = 0.97524$$\n\nComparing these values:\n$EU_{\\text{test}}(0.06) = 0.97524$\n$EU_{\\text{observe}}(0.06) = 0.97000$\n$EU_{\\text{treat}}(0.06) = 0.96200$\n\nThe maximum expected utility is $0.97524$, which corresponds to the \"Test\" strategy. The decision is encoded as follows: $0$ for observe, $1$ for test, and $2$ for treat. Thus, the decision code is $1$.\n\nThe optimal strategy depends on the pre-test probability $p$. The decision regions are determined by the intersections of the utility functions.\n- For $p  p_{\\text{test}} \\approx 0.02597$, \"Observe\" is optimal.\n- For $p_{\\text{test}}  p  p_{\\text{test-treat}}$, where $p_{\\text{test-treat}}$ is the intercept of $EU_{\\text{test}}$ and $EU_{\\text{treat}}$, \"Test\" is optimal.\n- For $p > p_{\\text{test-treat}}$, \"Treat\" is optimal.\nThe value $p_0 = 0.06$ falls in the \"Test\" region since $0.02597  0.06  0.1$ (and also less than the test-treat threshold, which is $\\approx 0.348$). Our calculation confirms that \"Test\" is the optimal action.\n\nThe final answer consists of the testing threshold, the treatment threshold (as defined by the problem), and the decision code for $p_0 = 0.06$.\n- Testing threshold: $0.02597$\n- Treatment threshold: $0.1000$\n- Decision code: $1$", "answer": "$$\\boxed{\\begin{pmatrix} 0.02597  0.1000  1 \\end{pmatrix}}$$", "id": "4952591"}]}